Germany is the first European country to launch ublituximab, with further launches throughout Europe to follow
Dr. Jörg-Thomas Dierks, CEO of Neuraxpharm, said: “Today’s launch is a significant breakthrough for people with RMS. The launch marks an important milestone for Neuraxpharm and reinforces our strategy to bring innovative treatments to our CNS patients.
“We are committed to making it available to as many patients as possible via our established network of neurology experts.”
Ublituximab is now the only B-cell depleting therapy approved for relapsing multiple sclerosis (RMS) that is administered in a 1-hour infusion, twice per year.
The roll out follows Neuraxpharm’s agreement with TG Therapeutics, announced in August 2023, to commercialise ublituximab outside the U.S., Canada, Mexico and excluding certain Asian countries that have been previously partnered.
According to Neuraxpharm, the new launch strengthens its position as an innovation company specializing in CNS disorders.
It is also the first step in the company’s plans to make this product available to patients across Europe and beyond over the coming years.
